Genome-Wide Association Studies in Idiopathic Pulmonary Fibrosis: Bridging the Gap between Sequence and Consequence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Multi-omics insights into the mechanisms and prognosis of IPF.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026
   Review
2. Ectopic Expansion of Pulmonary Vasculature in Fibrotic Lung Disease and Lung Adenocarcinoma Marked by Proangiogenic COL15A1+ Endothelial Cells.Pulmonary circulation · 2025
   Article
3. Vanadium Pentoxide Exposure Causes Strain-Dependent Changes in Mitochondrial DNA Heteroplasmy, Copy Number, and Lesions, but Not Nuclear DNA Lesions.International journal of molecular sciences · 2023
   Article
4. Update in Interstitial Lung Disease 2020.American journal of respiratory and critical care medicine · 2021
   Review

Corrections and comments

• Comment on
  Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.2020

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as